A Phase 1, Open-Label Study to Assess Comparative Bioavailability and Effect of Food on a Prototype Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir Versus Individual Dosage Forms Taken Concomitantly in Healthy Adult Subjects
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Bemnifosbuvir/Ruzasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Atea Pharmaceuticals
Most Recent Events
- 19 Sep 2024 Status changed from recruiting to completed.
- 31 Jul 2024 Planned End Date changed from 12 Feb 2024 to 13 Aug 2024.
- 31 Jul 2024 Planned primary completion date changed from 12 Feb 2024 to 13 Aug 2024.